ArticlePloS one2025
Association between homocysteine levels and hypertension prevalence as well as all-cause mortality and cardiovascular mortality among hypertensive patients: A population-based study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, some studies have investigated the relationship between homocysteine (Hcy) levels and hypertension. However, within the population of individuals with hypertension, there is still a lack of relevant research data. Therefore, we utilized data from the National Health and Nutrition Examination Survey (NHANES) to explore the associations between Hcy levels and hypertension prevalence, all-cause mortality, and cardiovascular mortality, in order to understand the role of Hcy levels in the control, assessment, and treatment of hypertension.
methodsIn this study, the data utilized were derived from NHANES, which collected data from 1999 to 2006. A total of 7680 eligible participants were ultimately included. To explore the associations between Hcy levels and hypertension prevalence as well as blood pressure, a weighted multivariate linear regression model and restricted cubic splines were employed to adjust for confounding factors. Additionally, we conducted subgroup analyses to observe the associations between Hcy levels and hypertension prevalence, systolic blood pressure(SBP), and diastolic blood pressure (DBP) in different subgroups. Lastly, we employed Kaplan-Meier estimates and Cox proportional hazards regression models for survival analysis, elucidating the relationship between hyperhomocysteinemia (HHcy) and the risks of all-cause mortality and cardiovascular mortality among hypertensive patients.
resultsThe average age of all participants was 44.82 years, with 51.8% being female. After adjusting for relevant covariates, a positive correlation between Hcy and the risk of hypertension was identified (OR=1.04, 95% CI: 1.02-1.07, P < 0.001). Multivariate linear regression results indicated a positive correlation between HHcy and blood pressure levels (SBP: β = 0.2, 95% CI: 0.10-0.30, P < 0.001; DBP: β = 0.09, 95% CI: 0.01-0.17, P < 0.05). Furthermore, restricted cubic spline(RCS) curve analysis revealed a nonlinear positive correlation between SBP and DBP with Hcy levels. Survival analysis results demonstrated that when blood Hcy concentrations exceeded 10 μmol/L, patients with hypertension experienced significantly increased all-cause and cardiovascular mortality rates (P < 0.001).
conclusionOur research validates Hcy as an independent risk factor for hypertension, further confirming a nonlinear positive correlation between blood pressure and Hcy levels. HHcy was associated with small increases SBP and DBP proportional to the degree of homocysteine elevation. Additionally, HHcy was a high-risk factor for all-cause and cardiovascular mortality in hypertensive patients. This may provide new insights into the management and treatment of hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.